A detailed history of Citigroup Inc transactions in Argenx Se stock. As of the latest transaction made, Citigroup Inc holds 6,531 shares of ARGX stock, worth $4.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,531
Previous 7,194 9.22%
Holding current value
$4.1 Million
Previous $3.09 Million 14.52%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$434.22 - $551.9 $287,887 - $365,909
-663 Reduced 9.22%
6,531 $3.54 Million
Q2 2024

Aug 12, 2024

BUY
$356.01 - $451.55 $770,049 - $976,702
2,163 Added 42.99%
7,194 $3.09 Million
Q1 2024

May 10, 2024

BUY
$356.95 - $413.29 $121,719 - $140,931
341 Added 7.27%
5,031 $1.98 Million
Q4 2023

Feb 09, 2024

SELL
$338.91 - $506.01 $6.29 Million - $9.4 Million
-18,567 Reduced 79.83%
4,690 $1.78 Million
Q3 2023

Nov 09, 2023

BUY
$369.35 - $548.43 $7.54 Million - $11.2 Million
20,427 Added 721.8%
23,257 $11.4 Million
Q2 2023

Aug 10, 2023

BUY
$360.14 - $422.58 $473,944 - $556,115
1,316 Added 86.92%
2,830 $1.1 Million
Q1 2023

May 11, 2023

BUY
$334.23 - $403.65 $93,918 - $113,425
281 Added 22.79%
1,514 $564,000
Q4 2022

Feb 09, 2023

SELL
$342.17 - $402.31 $85,200 - $100,175
-249 Reduced 16.8%
1,233 $467,000
Q3 2022

Nov 10, 2022

BUY
$343.2 - $395.75 $54,568 - $62,924
159 Added 12.02%
1,482 $522,000
Q2 2022

Aug 10, 2022

SELL
$269.58 - $378.88 $44,750 - $62,894
-166 Reduced 11.15%
1,323 $502,000
Q1 2022

May 12, 2022

BUY
$254.45 - $351.06 $37,913 - $52,307
149 Added 11.12%
1,489 $470,000
Q4 2021

Feb 10, 2022

SELL
$272.01 - $353.03 $154,229 - $200,168
-567 Reduced 29.73%
1,340 $469,000
Q3 2021

Nov 10, 2021

BUY
$295.0 - $350.58 $562,565 - $668,556
1,907 New
1,907 $576,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.